Hematology Deal Benchmarks
Leukemia, lymphoma, myeloma, sickle cell, and hemophilia deal benchmarks. Benchmarks derived from 73 verified transactions.
73
Total Deals
$723M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
28
license
24
acquisition
19
collaboration
1
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Poseida Therapeutics → Roche P-BCMA-ALLO1 | acquisition | $1.5B | $1.5B | Nov 2024 |
Syndax Pharmaceuticals → Incyte aml | collaboration | $200M | $1.4B | Jul 2024 |
MorphoSys → Novartis myelofibrosis | acquisition | $2.9B | $2.9B | Jul 2024 |
Imago BioSciences → Merck myelofibrosis | acquisition | $1.4B | $1.4B | Jul 2024 |
Keros Therapeutics → Takeda anemia | license | $200M | $200M | Jul 2024 |
Curon Biopharmaceutical → Merck hematologic_malignancies | acquisition | $700M | $1.3B | Jul 2024 |
Disc Medicine → Novo Nordisk thalassemia | license | $100M | $1.2B | Jul 2024 |
Orna Therapeutics → Vertex Pharmaceuticals Circular RNA gene editing | collaboration | $65M | $700M | Mar 2024 |
Prime Medicine → Bristol Myers Squibb Prime gene editing CAR-T | collaboration | $110M | $3.6B | Jan 2024 |
Legend Biotech → Novartis LB2102 | license | $100M | $1.2B | Nov 2023 |
Benchmark Your Hematology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 73 verified hematology transactions.
Run Hematology Benchmark